Catalyst
Slingshot members are tracking this event:
European Commission Approves Exelixis' (EXEL) Cabometyx for Treatment of Adults With Advanced Renal Cell Carcinoma
Do you think this event is important to the companies below? How will it affect their stock price?
Slingshot Insights Explained
Catalyst Date
Occurred on:
Sep 14, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Milestone Payment, European Commission Approval, Cabometyx, Advanced Renal Cell Carcinoma
